Effects of Fufang Biejia Ruangan Pills on hepatic fibrosis in vivo and in vitro

Table 1 Effect of Fufang Biejia Ruangan Pill on serum levels (mean ± SD)

Group	ALT(U/L)	AST(U/L)	PCIII (μg/mL)	HA (ng/mL)	LN (ng/mL)	CIV (ng/mL)
Control	23.8 ± 8.5b	30.0 ± 11.4b	15.16 ± 15.12b	205.30 ± 48.92a	82.02 ± 8.86	21.71 ± 1.76
Model	62.0 ± 23.7	98.8 ± 40.0	35.73 ± 17.90	563.82 ± 335.54	89.57 ± 7.59	29.20 ± 6.17
FFBJRGP-treated	50.02 ± 3.7	57.2 ± 30.0b	30.18 ± 9.41	456.18 ± 410.83	85.46 ± 7.51	28.02 ± 9.45
Colchicine-treated	46.1 ± 14.8	66.0 ± 33.2a	34.08 ± 9.19	313.17 ± 230.06a	88.61 ± 8.97	29.22 ± 7.95

^aP < 0.05,

^bP < 0.01 vs model group. ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; PCIII: Type III procollagen; HA: Hyaluronic acid; LN: Laminin; CIV: Type IV collagen; FFBJRGP: Fufang Biejia Ruangan Pill.

Table 2 Liver histopathological semiquantitative scores (mean ± SD)

Group	n	Scores					Staging scores
		0	I	II	III	IV
Control	6	6					0.00 ± 0.00b
Model	13				2	11	26.08 ± 5.85
FFBJRGP-treated	9				4	5	20.33 ± 6.12b
Colchicine-treated	9		1	3	5	2	19.00 ± 6.38b

^bP < 0.01 vs model group. FFBJRGP: Fufang Biejia Ruangan Pill.

Table 3 Expression of transforming growth factor-β1 and Smad3 (mean ± SD)

Groups	TGF-β1/β-actin	Smad3/β-actin
Control	1.00 ± 0.00b	0.62 ± 0.08b
Model	3.29 ± 2.08	1.33 ± 0.10
FFBJRGD-treated	2.08 ± 0.57	0.95 ± 0.12b
Colchicine-treated	2.25 ± 0.82	1.15 ± 0.06b

^bP < 0.01 vs model group. TGF-β: Transforming growth factor-β; FFBJRGP: Fufang Biejia Ruangan Pill.